Sfoglia per AUTORE
SIMO M
Collezione ASL Torino 4

  

Items : 3

Confirmed disability progression as a marker of permanent disability in multiple sclerosis. in European journal of neurology / Eur J Neurol. 2022 Aug;29(8):2321-2334. doi: 10.1111/ene.15406. Epub 2022 Jun 9.

2022
ASL Torino 4

Boz C; Shaygannejad V; van Pesch V; Cartechini E; Kappos L; Lechner-Scott J; Bergamaschi R; Lugaresi A; Grand'Maison F; Grammond P; Sola P; Ferraro D; Terzi M; Gerlach O; Alroughani R; Eichau S; Trojano M; Prat A; Girard M; Duquette P; Onofrj M; Sharmin S; Bovis F; Malpas C; Horakova D; Havrdova EK; Izquierdo G; Macdonell R; Dominguez JA; et alii...

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. in Multiple sclerosis and related disorders / Mult Scler Relat Disord. 2020 Feb;38:101868. doi: 10.1016/j.msard.2019.101868. Epub 2019 Nov 25.

2020
ASL Torino 4

Kunchok A; Malpas C; Nytrova P; Havrdova EK; Alroughani R; Terzi M; Yamout B; Hor JY; Karabudak R; Boz C; Ozakbas S; Olascoaga J; Simo M; Granella F; Patti F; McCombe P; Csepany T; Singhal B; Bergamaschi R; Fragoso Y; Al-Harbi T; Turkoglu R; Lechner-Scott J; Laureys G; Oreja-Guevara C; Pucci E; Sola P; Ferraro D; Altintas A; et alii...

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. in The Lancet. Neurology / Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.

2017
ASL Torino 4

Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; et alii...